A
Ashleigh O'Connell
Researcher at Pfizer
Publications - 18
Citations - 783
Ashleigh O'Connell is an academic researcher from Pfizer. The author has contributed to research in topics: Myeloid leukemia & Cytarabine. The author has an hindex of 7, co-authored 17 publications receiving 573 citations.
Papers
More filters
Journal ArticleDOI
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Jorge E. Cortes,Florian H. Heidel,Andrzej Hellmann,Walter Fiedler,B. Douglas Smith,Tadeusz Robak,Pau Montesinos,Daniel A. Pollyea,Pierre Desjardins,Oliver G. Ottmann,Weidong Wendy Ma,Naveed Shaik,A. Douglas Laird,Mirjana Zeremski,Ashleigh O'Connell,Geoffrey Chan,Michael Heuser +16 more
TL;DR: Glasdegib plus LDAC has a favorable benefit–risk profile and may be a promising option for AML patients unsuitable for intensive chemotherapy and clinical efficacy was evident across patients with diverse mutational profiles.
Journal ArticleDOI
Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study
Giovanni Martinelli,Vivian G. Oehler,Cristina Papayannidis,Rachel Courtney,Naveed Shaik,Xiaoxi Zhang,Ashleigh O'Connell,Karen McLachlan,Xianxian Zheng,Jerald P. Radich,Michele Baccarani,Hagop M. Kantarjian,Wendy J. Levin,Jorge E. Cortes,Catriona Jamieson +14 more
TL;DR: The maximum tolerated dose and the recommended phase 2 dose of the selective Hedgehog antagonist PF-04449913 in myeloid malignancies are identified and are being tested in phase 2 studies in patients with myelodysplastic syndrome, acuteMyeloid leukaemia, and myelofibrosis.
Journal ArticleDOI
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.
Jorge E. Cortes,B. Douglas Smith,Eunice S. Wang,Akil Merchant,Vivian G. Oehler,Martha Arellano,Daniel J. DeAngelo,Daniel A. Pollyea,Mikkael A. Sekeres,Tadeusz Robak,Weidong Wendy Ma,Mirjana Zeremski,Naveed Shaik,A. Douglas Laird,Ashleigh O'Connell,Geoffrey Chan,Mark A. Schroeder +16 more
TL;DR: Glasdegib plus cytarabine/daunorubicin was well tolerated and associated with clinical activity in patients with untreated AML or high‐risk MDS, suggesting potential benefit across diverse molecular profiles.
Journal ArticleDOI
Phase Ib Study of Glasdegib, A Hedgehog Pathway Inhibitor, in Combination With Standard Chemotherapy in Patients With AML or High-Risk MDS
Michael R. Savona,Daniel A. Pollyea,Wendy Stock,Vivian G. Oehler,Mark A. Schroeder,Jeffrey E. Lancet,James K. McCloskey,Hagop M. Kantarjian,Weidong Wendy Ma,Naveed Shaik,A. Douglas Laird,Mirjana Zeremski,Ashleigh O'Connell,Geoffrey Chan,Jorge E. Cortes +14 more
TL;DR: Treatment with glasdegib in combination with standard chemotherapy was generally well-tolerated and consistent with prior findings, warranting further evaluation of glas Degib-based combinations in patients with AML or high-risk MDS.
Journal ArticleDOI
A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Jorge E. Cortes,Florian H. Heidel,Michael Heuser,Walter Fiedler,B. Douglas Smith,Tadeusz Robak,Pau Montesinos Fernandez,Weidong Wendy Ma,Naveed Shaik,Mirjana Zeremski,Ashleigh O'Connell,Geoffrey Chan +11 more
TL;DR: The addition of glasdegib to standard chemotherapy (CT) has an acceptable safety profile and appears to have clinical activity in MDS and acute myeloid leukemia (AML) patients, particularly in previously untreated AML or high-risk MDS patients.